GLP-1 Use Linked to Macular Degeneration Risks

New research evaluates the association between popular diabetes medications and age-related eye conditions.

Updated on Oct. 21, 2026 in Diabetes

Isometric editorial illustration of a stylized geometric iris and pupil, representing clinical medical research into eye health conditions. — Researchers analyzing data from 300 million patients found that adjusting for underlying conditions significantly altered potential links between GLP-1 medications and macular degeneration. AI Illustration. Upload story photo >

Live Poll

Does learning about potential medication side effects change your trust in prescribed treatments?

Researchers recently analyzed data from over 300 million patients to investigate potential links between GLP-1 receptor agonist use and age-related macular degeneration. The study findings were presented at the American Academy of Ophthalmology annual meeting.

Why it matters

Determining whether these medications influence eye health is critical as millions of patients rely on them for diabetes management. The findings highlight the complex role of underlying health conditions in interpreting clinical data.

The study cohort included over 300 million total patients, with 15,385,073 patients identified as having GLP-1 receptor agonist exposure. Crude analysis showed odds ratios of 1.68, 1.89, and 1.53 for any, dry, and wet macular degeneration respectively.

The players

American Academy of Ophthalmology

This is the world's largest association of eye physicians and surgeons which facilitates clinical research and scientific exchange.

The details

The researchers employed Mantel-Haenszel adjustments to account for cardiometabolic variables, which significantly altered initial findings. For instance, adjusting for type 2 diabetes mellitus reversed the odds ratio for any macular degeneration to 0.69.

October 9 to 12, 2026: The American Academy of Ophthalmology held its annual meeting in New Orleans.
October 21, 2026: The study findings were published.

Health Landscape

The study utilized the Epic Cosmos database to evaluate longitudinal patient data on a massive scale. This research reflects a broader trend of leveraging large-scale electronic health record networks to conduct observational studies that bridge gaps in clinical knowledge.

Patients taking GLP-1 medications should consult with their healthcare providers regarding any concerns about eye health or vision changes. These results indicate that underlying conditions like diabetes and hypertension play a significant role in individual risk profiles.

The takeaway

While initial crude data suggested higher risks, adjusting for factors like diabetes and hypertension shifted these outcomes significantly. Readers should maintain regular eye screenings as part of their routine healthcare to monitor for age-related conditions.